Photo from wikipedia
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) has significant therapeutic efficacy in non‐small‐cell lung cancer (NSCLC) patients. However, acquired resistance is inevitable and limits the long‐term efficacy of EGFR‐TKI.… Click to show full abstract
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) has significant therapeutic efficacy in non‐small‐cell lung cancer (NSCLC) patients. However, acquired resistance is inevitable and limits the long‐term efficacy of EGFR‐TKI. Our study aimed to investigate the role of ras‐associated binding protein 25 (Rab25) in mediating EGFR‐TKI resistance in NSCLC.
Keywords:
egfr tki;
promotes erlotinib;
erlotinib resistance;
resistance;
rab25;
rab25 promotes
Journal Title: Cell Proliferation
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cell Proliferation
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!